PLM60 for Peripheral T Cell Lymphoma (PTCL)

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Peripheral T Cell Lymphoma

In brief

This is a Phase 1-2, randomized, multicenter, open label study of PLM60 administered via intravenous (IV) infusion in 28 day treatment cycles to adult participants with relapsed or refractory Peripheral T Cell Lymphoma (PTCL).

Key facts

Study ID

NCT03553914

Run by

Conjupro Biotherapeutics, Inc.

People needed

0

Starts

2021-01-01

Expected to finish

2025-01-01

Last updated by the study team

2020-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Gabrail Cancer Center — Canton, Ohio, United States
• Gabrial Cancer Center — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.